Akeret, Kevin
Buzzi, Raphael M.
Saxenhofer, Moritz
Bieri, Kathrin
Chiavi, Deborah
Thomson, Bart R.
Grüttner-Durmaz, Manuela
Schwendinger, Nina
Humar, Rok
Regli, Luca
van Doormaal, Tristan P. C.
Held, Ulrike
Keller, Emanuela
Hugelshofer, Michael http://orcid.org/0000-0002-3057-0472
Schaer, Dominik J.
Zuercher, Adrian
Grob, Alexandra
Abdulazim, Amr
Grüter, Basil
Roder, Constantin
Wirz, Danielle
Colombo, Elisa
Schubert, Gerrit A.
Hostettler, Isabelle
Hägler, Joshua
Etminan, Nima
Helmers, Muriel
Bozinov, Oliver
Wang, Sophie
Gentinetta, Thomas
Kälin, Vincens
,
Funding for this research was provided by:
CSL Behring AG, Berne, Switzerland
Swiss National Science Foundation (310030_197823)
Innosuisse - Schweizerische Agentur für Innovationsförderung (36361 IP-LS)
Uniscientia Foundation
Forschungskredit of the University of Zurich (21-021, 20-025)
Article History
Received: 22 November 2021
Accepted: 7 July 2022
First Online: 18 July 2022
Declarations
:
: The HeMoVal study is conducted in accordance with the Declaration of Helsinki and national and international standards of ICH-GCP E6(R2). Potential participants or their legal representatives receive detailed written and oral information on the study procedures and all participants or their legal representatives provide written informed consent. The study protocol will be approved by the local ethics committees of all participating study sites. At the time of submission, the study protocol has been approved by the ethics committee of the Canton of Zurich, Switzerland (KEK 2021–01023) for Zurich (CH), Aarau (CH), and St. Gallen (CH). The HeMoVal study has been registered on August 10, 2021 at ExternalRef removed, with the identifier NCT04998370.
: Not applicable.
: DS, MH, RMB and KA are inventors on provisional patent applications on the use of haptoglobin and hemopexin in aSAH. This research project is supported by CSL Behring AG, Berne, Switzerland.